These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16493620)

  • 21. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
    Al-Batran SE; Kerber A; Atmaca A; Dechow C; Reitsamer E; Schmidt S; Kolassa Y; Neumann A; Weidmann E; Hartmann JT; Jäger E
    Onkologie; 2007 Feb; 30(1-2):29-34. PubMed ID: 17264523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin-induced immune pancytopenia.
    Taleghani BM; Meyer O; Fontana S; Ahrens N; Novak U; Borner MM; Salama A
    Transfusion; 2005 May; 45(5):704-8. PubMed ID: 15847658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A Case of Drug-Induced Thrombocytopenia Resulting from Sensitivity to Oxaliplatin].
    Masuda T; Nagai K; Sanada K
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2157-9. PubMed ID: 26805296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(1):31-8. PubMed ID: 12684591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
    Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
    [No Abstract]   [Full Text] [Related]  

  • 26. Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
    Niu J; Mims MP
    J Clin Oncol; 2012 Nov; 30(31):e312-4. PubMed ID: 22987080
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
    Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
    Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S
    Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?
    James E; Podoltsev N; Salehi E; Curtis BR; Saif MW
    Clin Colorectal Cancer; 2009 Oct; 8(4):220-4. PubMed ID: 19822513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaphylactic reaction to oxaliplatin: a case report.
    Larzillière I; Brandissou S; Breton P; Lingoungou A; Gargot D; Ramain JP; Harnois C
    Am J Gastroenterol; 1999 Nov; 94(11):3387-8. PubMed ID: 10566767
    [No Abstract]   [Full Text] [Related]  

  • 33. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
    Kuebler JP; Colangelo L; O'Connell MJ; Smith RE; Yothers G; Begovic M; Robinson B; Seay TE; Wolmark N
    Cancer; 2007 Nov; 110(9):1945-50. PubMed ID: 17853393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
    Jurado JM; Pajares B; Olmos D; Sevilla I; Alba E
    Ann Oncol; 2008 Dec; 19(12):2093-4. PubMed ID: 18977850
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
    Bautista MA; Stevens WT; Chen CS; Curtis BR; Aster RH; Hsueh CT
    J Hematol Oncol; 2010 Mar; 3():12. PubMed ID: 20346128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.
    Curtis BR; Hsu YS; Podoltsev N; Lacy J; Curtis S; Samuel MS; Zutavern K; DeSimone RA; Bougie DW; Aster RH
    Blood; 2018 Mar; 131(13):1486-1489. PubMed ID: 29439950
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
    Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.